When Ben Lamm founded Colossal Biosciences in 2021, critics dismissed the venture as science fiction masquerading as biotechnology. Four years later, the company has achieved what many considered impossible: bringing back dire wolves, a species extinct for over 12,500 years.
This breakthrough represents more than scientific curiosity—it signals a fundamental transformation in how humanity approaches extinction and conservation. The story behind this achievement reveals both technological innovation and a distinctive leadership approach that bridged traditional scientific disciplines.
Lamm’s background lies not in genetics but in technology entrepreneurship. Prior to founding Colossal, he launched and sold multiple successful technology companies including Hypergiant, an artificial intelligence firm serving defense and space industries. This outsider perspective proved crucial to reimagining the possibilities in genetic science.
“Traditional scientific funding models weren’t equipped to support the scale of research needed,” explains Dr. Andrew Phillips, geneticist and early collaborator with Colossal. “Ben created a framework that combined venture capital resources with academic rigor, breaking through institutional limitations.”
The initial dire wolf program assembled specialists across paleontology, genetics, computational biology, and veterinary medicine—disciplines that rarely collaborated previously. Lamm established what he termed “radical collaboration frameworks” that incentivized knowledge-sharing between specialists who traditionally published in entirely different journals.
Dr. Jennifer Martinez, computational biologist with the project, notes: “Ben encouraged approaches that academic institutions might consider too speculative. He created space for calculated scientific risk-taking while maintaining rigorous validation protocols.”
The technological approach diverged significantly from previous de-extinction attempts. Rather than pursuing straightforward cloning, Colossal developed a methodology termed “genetic restoration technology” that reconstructs extinct species gene sequence by gene sequence.
This process began with extracting fragmented DNA from well-preserved dire wolf specimens recovered primarily from the La Brea Tar Pits. Using advanced computational modeling, researchers identified crucial genetic markers that differentiated dire wolves from modern canids.
The team then isolated eight critical gene sequences that determine unique dire wolf characteristics. Using CRISPR gene editing technology, they modified gray wolf embryos to express these traits, creating genomes functionally equivalent to those of the original species.
The result: three healthy dire wolf pups named Romulus, Remus, and Khaleesi, born in late 2024. These animals display the physical characteristics identified in fossil records, including the distinctive white coat never depicted in fictional portrayals.
Lamm’s vision extended beyond scientific achievement to practical conservation applications. The company developed parallel programs adapting the same technologies to strengthen genetic diversity in critically endangered species, particularly the North American red wolf.
“The dire wolf program served as our proving ground,” Lamm explained in recent interviews. “The same techniques now have immediate applications for species currently facing extinction. We’re transforming conservation from managing decline to actively restoring genetic resilience.”
This approach has gained traction among conservation biologists previously skeptical of de-extinction technologies. Dr. William Chen, conservation geneticist at the Wildlife Conservation Society, initially criticized the dire wolf program as diverting resources from endangered species protection. He has since joined Colossal’s scientific advisory board.
“The genetic tools developed through this work provide unprecedented capabilities for endangered species conservation,” Chen acknowledges. “The program has demonstrated immediate applications beyond the headline achievement.”
The company maintains a distinctive operational model that balances commercial viability with scientific transparency. While protecting core intellectual property, Colossal has published complete genetic data for scientific review—an approach unusual in private biotechnology ventures.
For conservation biology, Lamm’s approach represents a paradigm shift. Instead of viewing extinction as a permanent endpoint, Colossal demonstrates how careful genetic restoration might reverse human-caused biodiversity losses. This reframes both scientific possibilities and ethical responsibilities toward endangered species.
The dire wolf program represents merely the beginning of planned work. The company maintains ongoing research into several extinct species with potential ecological significance and conservation applications. Each builds upon the breakthrough methodologies developed for Canis dirus.